Abstract:
The invention relates to novel methods and kits for treating or preventing disease through the administration of random copolymers comprising amino acids tyrosine (Y), phenylalanine (F), alanine (A), and lysine (K). The invention also relates to the treatment of autoimmune diseases, such as multiple sclerosis, and to the administration of random copolymers in treatment regimen comprising formulations that are administered at intervals greater than 24 hours, or to sustained release formulations which administer the copolymer over a period greater than 24 hours. The invention further relates to methods for conducting a pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the formulations or dosing regimens of random copolymer described herein.
Abstract:
The present invention provides methods and compositions for treating autoimmune diseases and other unwanted immune reactions comprising administering a copolymer that binds to one or more HLA-DQ molecules and modulates DQ-restricted T cell responses. The copolymers are random copolymers of amino acids and copolymers comprising anchor residues to facilitate binding to the DQ binding pockets.
Abstract:
A slot machine comprises a housing, a plurality of physical symbol-bearing reels mounted in the housing, and a display arrangement positioned in front of the reels and interchangeable in the same housing between at least two of the following: (i) a display panel without an interior cavity, (ii) a light-guiding panel having an illuminated interior, and (iii) a transmissive video display.
Abstract:
The invention relates to novel methods and kits for treating or preventing disease through the administration of random copolymers. The invention also relates to the treatment of autoimmune diseases, such as multiple sclerosis, and to the administration of random copolymers in treatment regimen comprising formulations that are administered at intervals greater than 24 hours, or to sustained release formulations which administer the copolymer over a period greater than 24 hours. The invention further relates to methods for conducting a pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the formulations or dosing regimens of random copolymer described herein.
Abstract:
The invention relates to novel methods and kits for treating or preventing disease through the administration of random copolymers. The invention also relates to the treatment of autoimmune diseases, such as multiple sclerosis, and to the administration of random copolymers in treatment regimen comprising formulations that are administered at intervals greater than 24 hours, or to sustained release formulations which administer the copolymer over a period greater than 24 hours. The invention further relates to methods for conducting a pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the formulations or dosing regimens of random copolymer described herein.
Abstract:
According to one aspect of the invention, a gaming machine for conducting a wagering game, comprising a physically configurable button panel and at least one mechanical button removably disposed in the button panel. The gaming machine also comprises an input panel disposed adjacent to the button to produce an output signal in response to a predetermined movement of the button and a controller for initiating a function in response to the output signal.
Abstract:
Recombinant enzymatically active glucocerebrosidase is produced by a eukaryotic cell. Also, a cell includes nucleic acid encoding enzymatically active glucocerebrosidase; also a eukaryotic organism contains such a cell. Also, a method for producing enzymatically active glucocerebrosidase includes steps of introducing glucocerebrosidase-encoding nucleic acid into a eukaryotic cell, causing the cell to express glucocerebrosidase, and purifying the glucocerebrosidase from the cell.
Abstract:
A lifting apparatus for manipulating manhole castings and the like having at least one pinch clamp with an inner leg and an outer leg opposing one another wherein the inner leg and the outer leg are engageable with the manhole casting. A foot of the pinch clamp is connected to at least one of the inner leg and the outer leg wherein the foot is wider than the width of the inner leg and the outer leg and is engageable with the manhole casting. A flexible support is pivotally connected to the pinch clamp and is connectable to a lifting device wherein the foot and the legs of the pinch clamp are engageable with the manhole casting when the flexible support is pulled taut. Preferably, the inner and outer legs are separate structures pivotally connected thereto. Alternatively, the inner and outer leg may be integrally fabricated from a one-piece structure. The flexible supports are connected to a connector which is connectable to a lifting device.
Abstract:
Recombinant enzymatically active glucocerebrosidase is produced by a eukaryotic cell. Also, a cell includes nucleic acid encoding enzymatically active glucocerebrosidase; also a eukaryotic organism contains such a cell. Also, a method for producing enzymatically active glucocerebrosidase includes steps of introducing glucocerebrosidase-encoding nucleic acid into a eukaryotic cell, causing the cell to express glucocerebrosidase, and purifying the glucocerebrosidase from the cell.
Abstract:
A liquid handling system includes flow network module structure that defines a contained array of flow channels and a plurality of valves for controlling liquid flow through the flow channel array. The flow network module structure is adapted to be connected to an external source for applying a pressure differential to the flow network array to produce liquid flow within passages of the array. Also incorporated in the flow network module is chamber structure that is connected to the flow channel array and that has port structure in an outer surface of the module structure. Valve structure on the module structure is movable between a first position in which the port structure is closed and a second position in which the port structure is opened, the valve structure including actuator structure for moving a valve member between the first and second positions. Liquid transfer structure, including transport structure and probe structure carried on the transport structure, is adapted to cause movement of the valve structure from its first position to its second position concurrently with the movement of the probe structure into alignment with the chamber port structure for delivery of a quantity of sample material to the sample chamber and subsequent flow through the flow network array for interaction with an auxiliary fluid and transfer to an associated utilization device under the influence of an external pressure source.